Figure 4 from Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
Year: 2023
Type: other
Abstract: HDACis increase SSTR2 surface expression and 177Lu-DOTATATE uptake in QGP-1 xenograft model. A, There was an increase in SSTR2 expression with CI-994 (5 mg/kg) after 10 days of treatment, though the change was not significant (control n = 9, treated n = 6). B, There was an increase in SSTR2 expression with CI-994 (10 mg/kg) after 10 days of treatment, though the change was not significant (control n = 9, treated n = 11). C, Higher 177Lu-DOTATATE uptake in QGP-1 tumors indicates increased SSTR2 expression and increased therapeutic potential. A significant increase of 177Lu-DOTATATE was observed in tumors of mice treated with CI-994 for 10 days at 5 mg/kg (P = 0.0175, control n = 9, treated n = 12). D, Persistent uptake of 177Lu-DOTATATE after a 72-hour interval without CI-994 was found, with a significant increase observed in mice treated with CI-994 at 7.5 mg/kg for 10 days (P = 0.0092, control n = 6, CI-994; 5 mg/kg) n = 7, CI-994 (7.5 mg/kg) n = 8. Each circle, square, or triangle represents one tumor. Data are expressed as mean ± SEM; *, P < 0.05; **, P < 0.01.
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4386485376